Grufity logoGrufity logo

Innoviva Inc Stock Research

INVA

12.68USD+0.26(+2.09%)Market Closed

Market Summary

USD12.68+0.26
Market Closed
2.09%

INVA Stock Price

INVA RSI Chart

INVA Valuation

Market Cap

884.8M

Price/Earnings (Trailing)

2.65

Price/Sales (Trailing)

2.34

EV/EBITDA

1.33

Price/Free Cashflow

3.04

INVA Price/Sales (Trailing)

INVA Profitability

EBT Margin

60.64%

Return on Equity

52.11%

Return on Assets

25.17%

Free Cashflow Yield

32.91%

INVA Fundamentals

INVA Revenue

Revenue Y/Y

-31.27%

Revenue Q/Q

-23.11%

INVA Earnings

Earnings (TTM)

334.2M

Earnings Y/Y

123.43%

Earnings Q/Q

973.17%

Price Action

52 Week Range

11.5720.71
(Low)(High)

Last 7 days

-2.8%

Last 30 days

-3.7%

Last 90 days

-6.6%

Trailing 12 Months

-18.6%

INVA Financial Health

Current Ratio

2.77

INVA Investor Care

Shares Dilution (1Y)

0.46%

Diluted EPS (TTM)

3.29

Peers (Alternatives to Innoviva)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
443.8B
96.0B
-4.81% 2.94%
23.17
4.62
5.02% 7.14%
313.5B
29.2B
-4.62% 48.31%
51.95
10.72
5.34% 1.02%
270.7B
59.0B
-4.68% 39.38%
17.74
4.59
27.84% 112.03%
248.1B
99.9B
-13.46% -13.81%
8.33
2.48
45.01% 53.21%
155.2B
46.7B
0.52% 19.86%
23.24
3.32
2.79% 223.53%
MID-CAP
4.9B
4.4B
7.51% -2.25%
-45.96
1.12
1.80% 57.67%
2.2B
659.0M
11.94% 39.90%
58.05
3.32
16.78% -53.92%
SMALL-CAP
1.8B
613.6M
16.73% -44.78%
-3.63
3.01
37.73% -7.19%
1.5B
3.1M
20.50% 54.60%
-4.79
474.09
-77.09% -12.24%
1.3B
-
32.06% -61.83%
-0.44
1.95
-4.11% -144.36%
1.1B
23.5M
11.91% 62.20%
-13.66
47.73
243.57% -1.04%
919.4M
112.7M
-2.41% -28.74%
-4.11
8.16
45.53% 40.26%
884.8M
-
-3.72% -18.56%
2.65
2.34
10.49% -16.07%
299.6M
49.7M
47.35% -29.01%
-5.05
6.02
28.95% 32.80%
94.1M
2.6B
-43.99% -88.43%
-0.03
0.04
-13.88% -4855.92%

Financials for Innoviva

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22021Q42021Q32021Q2
RevenueNaN%nullnull392375365
Operating Expenses-144.6%-59.8113417-9.32-
  S&GA Expenses102.9%49241619-
  R&D Expenses55.8%312011-
EBITDA60.1%441275478--
EBITDA Margin-44.2%0.68*1.22*---
Earnings Before Taxes66.7%408245445480-
EBT Margin-46.6%0.61*1.14*---
Interest Expenses1.9%17161919-
Net Income61.1%334208369398-
Net Income Margin-45.4%0.51*0.94*---
Free Cahsflow-21.8%291372364--
* denotes actual numbers (not divided by Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets16.7%1,3281,1381,107926887
  Current Assets13.6%455400318314237
    Cash Equivalents6.1%301284217202135
  InventoryInfinity%71----
  Net PPE-6.2%00000
  Goodwill188.6%1666--
  Current Liabilities30.2%16412610963
    LT Debt, Non Current0.1%444443443395392
Shareholder's Equity13.4%641565552415492
  Retained Earnings66.0%-136.60-402.20-403.14-456.15-466.49
  Additional Paid-In Capital-1.1%1,1711,1841,1831,2641,262
Shares Outstanding0.1%7070707069
Minority Interest-100.0%-17716611189
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-21.8%291372378364351
  Share Based Compensation93.4%73322
Cashflow From Investing59.0%-67.86-165.58-73.0444-251.85
Cashflow From Financing-271.2%-57.6334-370.86-452.50-442.94
  Dividend Payments-0----
  Buy BacksNaN%003940-
* denotes actual numbers (not divided by Millions)

Risks for INVA

What is the probability of a big loss on INVA?

66.2%


Probability that Innoviva stock will be more than 20% underwater in next one year

55.8%


Probability that Innoviva stock will be more than 30% underwater in next one year.

35.8%


Probability that Innoviva stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Innoviva was unfortunately bought at previous high price.

Drawdowns

Returns for INVA

Cumulative Returns on INVA

4.7%


7-Year Cumulative Returns

-3.8%


5-Year Cumulative Returns

-3.1%


3-Year Cumulative Returns

What are the long-term rolling returns for INVA?

FIve years rolling returns for Innoviva.

Annualized Returns

Which funds bought or sold INVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-01-25
Lindbrook Capital, LLC
reduced
-90.03
-9,715
1,285
-%
2023-01-25
GRIMES & COMPANY, INC.
reduced
-0.9
17,526
147,526
0.01%
2023-01-25
WHITTIER TRUST CO
unchanged
-
818
9,818
-%
2023-01-24
Louisiana State Employees Retirement System
reduced
-0.67
47,000
395,000
0.01%
2023-01-23
Allspring Global Investments Holdings, LLC
added
438.68
3,007,440
3,591,440
0.01%
2023-01-20
Prairiewood Capital, LLC
reduced
-1.12
117,068
1,028,070
0.76%
2023-01-20
Diligent Investors, LLC
sold off
-100
-134,000
-
-%
2023-01-19
RITHOLTZ WEALTH MANAGEMENT
reduced
-43.66
-160,633
289,367
0.02%
2023-01-18
Maryland State Retirement & Pension System
new
-
340,446
340,446
0.01%
2023-01-18
Verition Fund Management LLC
added
199.88
293,000
508,000
-%

1–10 of 45

Latest Funds Activity

Are funds buying INVA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own INVA
No. of Funds

Innoviva News

MarketBeat

DekaBank Deutsche Girozentrale Sells 17115 Shares of Innoviva ....

MarketBeat,
22 hours ago

The News Heater

InvestorsObserver

MarketBeat

ValueWalk

InvestorPlace

StockNews.com

Schedule 13G FIlings of Innoviva

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 20, 2023
blackrock inc.
10.6%
5,671,100
SC 13G
Jul 11, 2022
vanguard group inc
10.00%
6,970,950
SC 13G/A
Feb 11, 2022
renaissance technologies llc
7.62%
5,295,133
SC 13G/A
Feb 01, 2022
westfield capital management co lp
5.3%
3,683,485
SC 13G
Jan 28, 2022
blackrock inc.
13.0%
9,008,758
SC 13G/A
Jun 07, 2021
renaissance technologies llc
10.79%
7,491,342
SC 13G/A
May 25, 2021
sarissa capital management lp
9.24%
6,414,000
SC 13D/A
May 25, 2021
glaxosmithkline plc
0%
0
SC 13D/A
Feb 12, 2021
glaxosmithkline plc
31.6%
32,005,260
SC 13D/A
Feb 11, 2021
renaissance technologies llc
7.77%
7,881,802
SC 13G/A

INVA Fair Value

Recent SEC filings of Innoviva

View All Filings
Date Filed Form Type Document
Jan 20, 2023
SC 13G
Major Ownership Report
Jan 12, 2023
4
Insider Trading
Jan 10, 2023
SC 13D/A
13D - Major Acquisition
Jan 06, 2023
3
Insider Trading
Jan 04, 2023
8-K
Current Report
Nov 22, 2022
4
Insider Trading
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Oct 28, 2022
8-K/A
Current Report

Latest Insider Trading transactions for INVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-18
Zhen Marianne
sold (taxes)
-11,219.4
13.55
-828
chief accounting officer
2022-11-15
Zhen Marianne
acquired
-
-
433
chief accounting officer
2022-08-19
Zhen Marianne
sold (taxes)
-11,719.6
14.12
-830
chief accounting officer
2022-05-20
Zhen Marianne
sold (taxes)
-13,488.1
16.29
-828
chief accounting officer
2022-05-13
Zhen Marianne
acquired
-
-
1,834
chief accounting officer
2022-04-25
Haimovitz Jules
acquired
-
-
12,647
-
2022-04-25
Birx Deborah
acquired
-
-
12,647
-
2022-04-25
Odysseas Kostas D
acquired
-
-
12,647
-
2022-04-25
DiPaolo Mark
acquired
-
-
12,647
-
2022-04-25
Schlesinger Sarah J.
acquired
-
-
12,647
-

1–10 of 50

Pavel Raifeld
5
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

INVA Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 67,257$ 97,862$ 265,536$ 284,186
Expenses:    
Selling, general and administrative27,8102,86046,08413,074
Research and development11,72544931,447536
Amortization of intangible assets1,51101,5110
Gain on sale of Theravance Respiratory Company, LLC ("TRC")(266,696)0(266,696)0
Loss on extinguishment of debt0020,6620
Changes in fair values of equity and long-term investments, net(130)(33,613)67,881(133,973)
Interest and dividend income(2,135)(453)(3,181)(503)
Interest expense5,0964,79011,76114,229
Other expense (income), net(28)6527502,036
Total expenses(219,167)(25,315)(86,101)(104,601)
Income before income taxes286,424123,177351,637388,787
Income tax expense net57,07720,53163,06165,600
Net income (loss)229,347102,646288,576323,187
Net income (loss) attributable to noncontrolling interests(36,176)30,2086,34167,678
Net income attributable to Innoviva stockholders$ 265,523$ 72,438$ 282,235$ 255,509
Basic net income per share attributable to Innoviva stockholders$ 3.81$ 1.04$ 4.05$ 2.96
Diluted net income per share attributable to Innoviva stockholders$ 2.80$ 0.90$ 3.07$ 2.63
Shares used to compute Innoviva basic and diluted net income per share:    
Shares used to compute basic net income per share69,73169,45869,64086,298
Shares used to compute diluted net income per share95,83081,69995,07298,536
Royalty revenue from a related party    
Revenue:    
Total revenue$ 62,150$ 97,862$ 260,429$ 284,186
Net product sales    
Revenue:    
Total revenue5,10705,1070
Expenses:    
Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)$ 3,680$ 0$ 3,680$ 0

INVA Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 300,789$ 201,525
Short-term marketable securities2820
Accounts receivable6,7430
Receivables from collaboration arrangement65,606110,711
Inventory70,8070
Prepaid expenses7,9321,367
Other current assets2,43270
Total current assets454,591313,673
Property and equipment, net16512
Equity and long-term investments489,111483,845
Capitalized fees paid to a related party, net101,062111,430
Right-of-use assets3,67997
Goodwill15,9950
Intangible assets258,4890
Deferred tax assets, net017,327
Other assets4,62011
Total assets1,327,712926,395
Current liabilities:  
Accounts payable3,80527
Accrued personnel-related expenses6,473619
Accrued interest payable5,7024,152
Deferred revenue2,8490
Convertible subordinated notes due 2023, net of issuance costs96,1310
Income tax payable33,8040
Other accrued liabilities15,1201,009
Total current liabilities163,8845,807
Long-term debt, net of discount and issuance costs443,679394,653
Other long-term liabilities78,4210
Deferred tax liabilities3600
Commitments and contingencies (Note 11)
Stockholders' equity:  
Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding00
Common stock: $0.01 par value, 200,000 shares authorized, 69,776 and 69,566 issued and outstanding as of September 30, 2022 and December 31, 2021 respectively698696
Treasury stock: at cost, 32,005 shares as of September 30, 2022 and December 31, 2021, respectively(393,829)(393,829)
Additional paid-in capital1,171,0961,264,024
Accumulated deficit(136,597)(456,148)
Total Innoviva stockholders' equity641,368414,743
Noncontrolling interest0111,192
Total stockholders' equity641,368525,935
Total liabilities and stockholders' equity$ 1,327,712$ 926,395